JP2020529862A5 - - Google Patents

Info

Publication number
JP2020529862A5
JP2020529862A5 JP2020520425A JP2020520425A JP2020529862A5 JP 2020529862 A5 JP2020529862 A5 JP 2020529862A5 JP 2020520425 A JP2020520425 A JP 2020520425A JP 2020520425 A JP2020520425 A JP 2020520425A JP 2020529862 A5 JP2020529862 A5 JP 2020529862A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
percentage homology
variable region
Prior art date
Application number
JP2020520425A
Other languages
English (en)
Japanese (ja)
Other versions
JP7601635B2 (ja
JPWO2019005635A5 (https=
JP2020529862A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/039147 external-priority patent/WO2019005635A2/en
Publication of JP2020529862A publication Critical patent/JP2020529862A/ja
Publication of JP2020529862A5 publication Critical patent/JP2020529862A5/ja
Publication of JPWO2019005635A5 publication Critical patent/JPWO2019005635A5/ja
Priority to JP2023061568A priority Critical patent/JP7490109B2/ja
Application granted granted Critical
Publication of JP7601635B2 publication Critical patent/JP7601635B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020520425A 2017-06-25 2018-06-22 抗pd-1抗体とその作製及び使用方法 Active JP7601635B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023061568A JP7490109B2 (ja) 2017-06-25 2023-04-05 抗pd-1抗体とその作製及び使用方法

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201762524554P 2017-06-25 2017-06-25
US201762524558P 2017-06-25 2017-06-25
US201762524557P 2017-06-25 2017-06-25
US201762524553P 2017-06-25 2017-06-25
US62/524,554 2017-06-25
US62/524,558 2017-06-25
US62/524,557 2017-06-25
US62/524,553 2017-06-25
US201762545603P 2017-08-15 2017-08-15
US62/545,603 2017-08-15
PCT/US2018/039147 WO2019005635A2 (en) 2017-06-25 2018-06-22 ANTI-PD-1 ANTIBODIES AND METHODS OF PREPARATION AND USE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023061568A Division JP7490109B2 (ja) 2017-06-25 2023-04-05 抗pd-1抗体とその作製及び使用方法

Publications (4)

Publication Number Publication Date
JP2020529862A JP2020529862A (ja) 2020-10-15
JP2020529862A5 true JP2020529862A5 (https=) 2022-01-17
JPWO2019005635A5 JPWO2019005635A5 (https=) 2022-01-17
JP7601635B2 JP7601635B2 (ja) 2024-12-17

Family

ID=64742653

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020520425A Active JP7601635B2 (ja) 2017-06-25 2018-06-22 抗pd-1抗体とその作製及び使用方法
JP2023061568A Active JP7490109B2 (ja) 2017-06-25 2023-04-05 抗pd-1抗体とその作製及び使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023061568A Active JP7490109B2 (ja) 2017-06-25 2023-04-05 抗pd-1抗体とその作製及び使用方法

Country Status (5)

Country Link
US (1) US11466084B2 (https=)
EP (1) EP3645740A4 (https=)
JP (2) JP7601635B2 (https=)
CN (1) CN110799537B (https=)
WO (1) WO2019005635A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021006199A1 (ja) 2019-07-05 2021-01-14 小野薬品工業株式会社 Pd-1/cd3二重特異性タンパク質による血液がん治療
EP4011918A4 (en) 2019-08-08 2023-08-23 ONO Pharmaceutical Co., Ltd. DUAL SPECIFIC PROTEIN
CN116209466A (zh) * 2020-08-27 2023-06-02 上海君实生物医药科技股份有限公司 抗pd-1抗体在治疗鼻咽癌中的用途
EP4293046A4 (en) * 2021-02-10 2025-03-05 Shanghai Jemincare Pharmaceuticals Co., Ltd. Anti-pd-1 antibody and use thereof
CN116687933B (zh) * 2022-02-28 2025-10-31 中国科学院上海药物研究所 甲氨蝶呤及其药物组合物在肿瘤免疫治疗中的用途
WO2024160721A1 (en) 2023-01-30 2024-08-08 Kymab Limited Antibodies
CN119775428B (zh) * 2024-12-12 2025-08-05 广东沃博生物医药科技有限公司 一种免疫细胞的制备方法及其在治疗疾病中的用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CN1753912B (zh) * 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
RU2494107C2 (ru) * 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
HRP20131167T1 (hr) * 2007-06-18 2014-01-03 Merck Sharp & Dohme B.V. Antitijela za humani receptor programirane smrti pd-1
TW201134488A (en) * 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
CA2920113A1 (en) * 2013-08-20 2015-02-26 Merck Sharp & Dohme Corp. Treating cancer with a combination of a pd-1 antagonist and dinaciclib
TWI681969B (zh) * 2014-01-23 2020-01-11 美商再生元醫藥公司 針對pd-1的人類抗體
SG10201900002QA (en) * 2014-01-24 2019-02-27 Dana Farber Cancer Institue Inc Antibody molecules to pd-1 and uses thereof
KR102524920B1 (ko) * 2014-07-22 2023-04-25 아폴로믹스 인코포레이티드 항-pd-1 항체
WO2017019846A1 (en) * 2015-07-30 2017-02-02 Macrogenics, Inc. Pd-1-binding molecules and methods use thereof
PL3368572T3 (pl) * 2015-10-02 2022-09-12 Symphogen A/S Przeciwciała anty-PD-1 oraz kompozycje

Similar Documents

Publication Publication Date Title
JP2020529863A5 (https=)
JP2020529862A5 (https=)
JP2020531043A5 (https=)
JP7685095B2 (ja) 多重特異性抗体とその作製及び使用方法
JPWO2019005636A5 (https=)
JP2020530776A5 (https=)
IL276830B2 (en) Anti-claudin 18.2 antibodies and uses thereof
AU2022350588A1 (en) Antibody, antibody-drug conjugate thereof and use thereof
WO2021213434A1 (zh) 一种抗Nectin-4的抗体及其应用
JP7399852B2 (ja) 多重特異性抗体とその作製及び使用方法
CN110869389A (zh) 抗ror1抗体及其制备和使用方法
JPWO2019005638A5 (https=)
EP3328895A1 (en) Anti-pd-1 antibodies and uses thereof
RU2017114968A (ru) Связывающие молекулы, а именно антитела, способные связываться с l1cam (cd171)
JP2021501575A5 (https=)
CN110831972A (zh) 抗pd-l1抗体及其制备和使用方法
JPWO2020237173A5 (https=)
JPWO2019005635A5 (https=)
EP4242231A1 (en) Anti-siglec-15 antibody and application thereof in preparing drug
JPWO2019005634A5 (https=)
CA3147887A1 (en) Composition and methods of targeting the pre-b cell receptor for the treatment of leukemias and lymphomas
RU2024107459A (ru) Биспецифическое тетравалентное антитело против egfr и her3
CA3232304A1 (en) Use of anti-cd40 antibody
WO2025040000A1 (zh) 5t4抗体药物偶联物及其应用
HK40130188A (zh) Cd38和icam1抗体及其用途